Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Voyager's Parkinson's Gene Therapy Poised For Pivotal Trial Exploration

Executive Summary

The Cambridge, Mass.-based biotech announced updated data from a Phase Ib trial of a gene therapy for Parkinson's disease, showing improvements in motor function and less time with dyskinesia.

You may also be interested in...



Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident

The gene therapy developer described Sanofi's decision to give up ex-US rights to VY-AADC01 as good news, but its stock price fell anyway. Voyager maintains that it wasn't necessarily counting on its partner to opt in, so it has enough funding without Sanofi to conduct a Phase II/III study.

Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy

It isn’t just the cutting-edge science. Novartis’ landmark approval also highlights regulatory and reimbursement innovation and also may set the rules that the next wave of cell and gene therapies have to follow.

Spark Therapeutics' Vision Loss Gene Therapy Gets FDA Panel Review

Voretigene neparvovec moves closer to being the first to market a gene therapy in the US with FDA advisory committee review on Oct. 12.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel